• A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Ireland +5
  • Study of Zirconium-89 Girentuximab as a Diagnostic Tool for Patients with Von-Hippel Lindau Disease

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Italy
  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    3 1 1 1
    France
  • Study of SPN-817 (Huperzine A) in Adults with Focal Onset Seizures: Testing Safety and Effectiveness of Treatment

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Poland
  • Study of tamoxifen loading dose and Ki67 response in breast cancer patients before surgery (ENDO-67)

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study of Pozelimab and Cemdisiran in Adults with Paroxysmal Nocturnal Hemoglobinuria Not Responding Well to Current C5 Inhibitor Treatment

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain
  • Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    France
  • Study comparing amoxicillin/clavulanic acid treatment versus surgery for children with uncomplicated appendicitis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Comparison of two concentrations of levobupivacaine (0.

    Not yet recruiting

    3 1 1 1
    Spain
  • Study of ceftriaxone and amoxicillin treatment in patients with acute coronary syndrome, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction

    Not yet recruiting

    3 1 1 1
    Finland

powered by